Charles Schwab Investment Management Inc Janux Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 273,135 shares of JANX stock, worth $8.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
273,135
Previous 234,191
16.63%
Holding current value
$8.6 Million
Previous $10.6 Million
37.45%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding JANX
# of Institutions
229Shares Held
55.2MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$327 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$112 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$111 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$96.4 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$73.8 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.31B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...